A Novel Oncolytic Adenovirus Based on Simian Adenovirus Serotype 24

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 May 3

PMID 28460470

Citations 7

Authors

Tao Cheng

Yufeng Song

Yan Zhang

Chao Zhang

Jieyun Yin

Yudan Chi

Dongming Zhou

Affiliations

Soon will be listed here.

Abstract

Among the oncolytic virotherapy, an emerging treatment for tumor, adenoviruses are widely used at present in preclinical and clinical trials. Traditionally, oncolytic adenoviruses were developed based on the human adenovirus serotype 5 (AdHu5). However, AdHu5 has the drawbacks of preexisting anti-AdHu5 immunity in most populations, and extensive sequestration of Adhu5 by the liver through hexon, blood coagulation factor X (FX), and FX receptor interactions. To tackle these problems, we explored a novel oncolytic adenovirus AdC7-SP/E1A-ΔE3 for cancer treatment. AdC7-SP/E1A-ΔE3 was constructed by replacing the E1A promoter with tumor specific promoter survivin promoter and deleting E3 region using direct cloning methods based on simian adenovirus serotype 24 (namely AdC7). We showed that AdC7-SP/E1A-ΔE3 significantly killed tumor cell lines NCI-H508 and Huh7, and inhibited tumor growth in both NCI-H508 and Huh7 xenograft tumor models. Importantly, AdC7-SP/E1A-ΔE3 exhibited the antitumor efficacy via systemic administration. Mechanistically, infected cells were killed by AdC7-SP/E1A-ΔE3 via the p53-independent mitochondrial apoptosis pathway in which phosphorylation of BAD markedly declined and the expresses of Bik significantly went up. Therefore, AdC7-SP/E1A-ΔE3 is a promising candidate for liver and colon tumor treatment.

Citing Articles

Adenovirus-Neutralizing and Infection-Promoting Activities Measured in Serum of Human Brain Cancer Patients Treated with Oncolytic Adenovirus Ad5-∆24.RGD.

van der Meulen-Muileman I, Amado-Azevedo J, Lamfers M, Kleijn A, Idema S, Noske D Int J Mol Sci. 2025; 26(2.

PMID: 39859568 PMC: 11765819. DOI: 10.3390/ijms26020854.

[Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6].

Wang Q, Wang Y, Li Y, Xing M, Zhou D Sichuan Da Xue Xue Bao Yi Xue Ban. 2022; 53(1):71-76.

PMID: 35048603 PMC: 10408869. DOI: 10.12182/20220160504.

Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.

Bots S, Kemp V, Cramer S, van den Wollenberg D, Hornsveld M, Lamfers M Hum Gene Ther. 2021; 33(5-6):275-289.

PMID: 34861769 PMC: 8972008. DOI: 10.1089/hum.2021.216.

A potential bat adenovirus-based oncolytic virus targeting canine cancers.

Matsugo H, Kitamura-Kobayashi T, Kamiki H, Ishida H, Sekine W, Takenaka-Uema A Sci Rep. 2021; 11(1):16706.

PMID: 34408176 PMC: 8373906. DOI: 10.1038/s41598-021-96101-4.

Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?.

Bots S, Hoeben R Int J Mol Sci. 2020; 21(14).

PMID: 32650405 PMC: 7404033. DOI: 10.3390/ijms21144821.

References

Tarodi B, Subramanian T, Chinnadurai G . Functional similarity between adenovirus e1b 19k gene and bcl2 oncogene - mutant complementation and suppression of cell-death induced by DNA-damaging agents. Int J Oncol. 2011; 3(3):467-72. DOI: 10.3892/ijo.3.3.467. View

Huang T, Savontaus M, Shinozaki K, Sauter B, Woo S . Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther. 2003; 10(15):1241-7. DOI: 10.1038/sj.gt.3301987. View

Yu D, Sakamoto G, Henderson D . Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999; 59(7):1498-504. View

Banerjee S, Uppal T, Strahan R, Dabral P, Verma S . The Modulation of Apoptotic Pathways by Gammaherpesviruses. Front Microbiol. 2016; 7:585. PMC: 4847483. DOI: 10.3389/fmicb.2016.00585. View

Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T . Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst. 2006; 98(9):625-36. DOI: 10.1093/jnci/djj161. View

Wang X, Liu Q, Wang P, Wang Z, Tong W, Zhu B . Comparisons among sensitivities of different tumor cells to focused ultrasound in vitro. Ultrasonics. 2009; 49(6-7):558-64. DOI: 10.1016/j.ultras.2009.02.002. View

Cheng T, Wang X, Song Y, Tang X, Zhang C, Zhang H . Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1. Vaccine. 2016; 34(41):4875-4883. DOI: 10.1016/j.vaccine.2016.08.066. View

Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L . Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol. 2010; 84(19):10087-101. PMC: 2937776. DOI: 10.1128/JVI.02425-09. View

Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B . A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget. 2015; 6(15):13564-78. PMC: 4537034. DOI: 10.18632/oncotarget.3769. View

10.

Fueyo J, Gomez-Manzano C, Alemany R, Lee P, McDonnell T, Mitlianga P . A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000; 19(1):2-12. DOI: 10.1038/sj.onc.1203251. View

11.

Lorin C, Vanloubbeeck Y, Baudart S, Ska M, Bayat B, Brauers G . Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. PLoS One. 2015; 10(4):e0122835. PMC: 4391709. DOI: 10.1371/journal.pone.0122835. View

12.

Zheng J, Follis A, Kriwacki R, Moldoveanu T . Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 2015; 283(14):2690-700. DOI: 10.1111/febs.13527. View

13.

Zhou D, Zhou X, Bian A, Li H, Chen H, Small J . An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc. 2010; 5(11):1775-1785. PMC: 3994680. DOI: 10.1038/nprot.2010.134. View

14.

Tatsis N, Tesema L, Robinson E, Giles-Davis W, McCoy K, Gao G . Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2005; 13(5):421-9. DOI: 10.1038/sj.gt.3302675. View

15.

Pigault C, Follenius-Wund A, Schmutz M, Freyssinet J, Brisson A . Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. J Mol Biol. 1994; 236(1):199-208. DOI: 10.1006/jmbi.1994.1129. View

16.

Yuan M, Webb E, Lemoine N, Wang Y . CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses. Viruses. 2016; 8(3):72. PMC: 4810262. DOI: 10.3390/v8030072. View

17.

Dukhanin A, Romanova E, Dukhanina E . Molecular mechanisms of different sensitivity of tumor cells to dexamethasone. Bull Exp Biol Med. 2001; 131(1):73-6. DOI: 10.1023/a:1017594932500. View

18.

Garg H, Suri P, Gupta J, Talwar G, Dubey S . Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016; 16:49. PMC: 4917988. DOI: 10.1186/s12935-016-0326-1. View

19.

Sheehy S, Duncan C, Elias S, Collins K, Ewer K, Spencer A . Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011; 19(12):2269-76. PMC: 3242658. DOI: 10.1038/mt.2011.176. View

20.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker A . Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses. 2015; 7(11):6009-42. PMC: 4664994. DOI: 10.3390/v7112923. View